Detalles de la búsqueda
1.
Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Cancer
; 129(2): 283-295, 2023 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36408673
2.
Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost-effectiveness analysis.
Liver Int
; 43(10): 2292-2301, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592868
3.
Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
Gynecol Oncol
; 166(3): 582-588, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781166
4.
Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Oncologist
; 26(2): e290-e297, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32918790
5.
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
J Natl Compr Canc Netw
; 19(10): 1141-1147, 2021 08 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34348237
6.
First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.
Cost Eff Resour Alloc
; 19(1): 77, 2021 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34863203
7.
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.
J Gynecol Oncol
; 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38857909
8.
Combination tumor-treating fields treatment for patients with metastatic non-small cell lung cancer: A cost-effectiveness analysis.
Cancer Med
; 13(5): e7070, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38468503
9.
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis.
J Gynecol Oncol
; 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38576343
10.
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
J Gynecol Oncol
; 35(1): e2, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37477106
11.
Adverse events of biologic or small molecule therapies in clinical trials for inflammatory bowel disease: A systematic review and meta-analysis.
Heliyon
; 10(4): e25357, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38370239
12.
Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis.
Adv Ther
; 40(4): 1838-1849, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36870042
13.
First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.
Clin Genitourin Cancer
; 21(3): 417.e1-417.e10, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36529626
14.
Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis.
Therap Adv Gastroenterol
; 16: 17562848231207200, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37928895
15.
The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
J Ovarian Res
; 16(1): 168, 2023 Aug 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37605274
16.
First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis.
Front Public Health
; 11: 1028202, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37006537
17.
Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial.
Ther Adv Med Oncol
; 15: 17588359231206147, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37846397
18.
Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.
Front Endocrinol (Lausanne)
; 13: 909333, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35909569
19.
Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Front Immunol
; 13: 1044678, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36685541
20.
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
Front Immunol
; 13: 1103055, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36713376